Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Avalon GloboCare ( (ALBT) ) is now available.
On July 28, 2025, Avalon GloboCare‘s subsidiary, Q&A Distribution, LLC, entered into a distribution agreement with Saga Health Corporation for the KetoAir™ breathalyzer device. This device is designed for ketogenic health management and will be used in Saga Health’s Holistic Health Reset Program targeted at first responders. The partnership aims to expand the commercial reach of KetoAir™, which provides real-time insights into fat metabolism for users pursuing ketogenic diets.
More about Avalon GloboCare
Avalon GloboCare Corp. is a developer of precision diagnostic consumer products and advances intellectual property in cellular therapy. The company markets the KetoAir™ breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device, and plans to develop additional diagnostic uses for this technology. Avalon also owns and operates commercial real estate.
Average Trading Volume: 250,297
Technical Sentiment Signal: Sell
Current Market Cap: $6.71M
Learn more about ALBT stock on TipRanks’ Stock Analysis page.